Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

PPHMD

Peregrine Pharmaceuticals Inc. (MM) (PPHMD)

Peregrine Pharmaceuticals Inc. (MM)
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PPHMD
DateTimeSourceHeadlineSymbolCompany
03/29/20195:42PMBusiness WireAnnouncing VanEck Vectors ETFs’ March 2019 DistributionsNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
12/26/20185:37PMBusiness WireAnnouncing VanEck Vectors Equity ETFs December 2018 DistributionNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
10/17/201810:48AMBusiness WireVanEck Launches ESPO, ETF Focused on Fast Growing Video Game and eSports IndustryNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
09/28/20185:03PMBusiness WireAnnouncing VanEck Vectors Equity ETFs’ September 2018 DistributionsNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
06/29/20185:15PMBusiness WireAnnouncing VanEck Vectors Equity ETFs June 2018 DistributionsNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
03/29/20184:58PMBusiness WireAnnouncing VanEck Vectors Equity ETFs March 2018 DistributionsNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
11/10/20098:30AMPR Newswire (US)New Study in Clinical Cancer Research Shows Therapeutic Promise of Peregrine's Bavituximab With Radiation in a Lethal Brain CancNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
11/04/20091:17PMPR Newswire (US)Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting AntibodiesNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
11/03/20092:00PMPR Newswire (US)Peregrine Pharmaceuticals Regains Full Compliance With Nasdaq Continued Listing RequirementsNASDAQ:PPHMD
10/27/20097:17AMEdgar (US Regulatory)Current report filing (8-K)NASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
10/23/20094:34PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
10/21/20098:30AMPR Newswire (US)Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast CancerNASDAQ:PPHMD
10/19/20098:30AMPR Newswire (US)Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory AffairsNASDAQ:PPHMD
10/19/20097:30AMPR Newswire (US)Peregrine Pharmaceuticals 1:5 Reverse Stock Split Takes EffectNASDAQ:PPHMD
10/19/20096:44AMEdgar (US Regulatory)Current report filing (8-K)NASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
 Showing the most relevant articles for your search:NASDAQ:PPHMD